drugset / Trial / NCT04377659
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
Timeline
- Start
- 2020-05-01
- Primary completion
- 2022-10-28
- Completion
- 2022-10-28
Outcome
Outcome not reported
Stopped: “Based on two large, multicenter, randomized trials showed no benefit to tocilizumab in this setting and study has been closed.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |